6 studies found for:    ventirx
Show Display Options
Rank Status Study
1 Recruiting A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Motolimod;   Drug: Cetuximab;   Drug: Nivolumab
2 Active, not recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo
3 Active, not recruiting VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD);   Drug: VTX-2337;   Drug: Placebo
4 Terminated
Has Results
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Condition: Low Grade B Cell Lymphoma
Intervention: Drug: VTX-2337 plus radiotherapy
5 Completed Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
Conditions: Advanced Solid Tumors;   Lymphoma
Intervention: Drug: VTX-2337
6 Active, not recruiting A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated
Condition: Ovarian Cancer
Interventions: Drug: Motolimod;   Drug: Durvalumab;   Drug: Pegylated Liposomal Doxorubicin

Indicates status has not been verified in more than two years